A study showed that RNF5 inhibited the progression of NASH by down-regulating lipid metabolism genes (CD36, SCD1, ACACA, and PPARG) and inflammatory genes (IL-6, CXCL2, and TNF) through targeted degradation of Hrd1 via the ubiquitin-mediated proteasome pathway (123). The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.